Silencing of ocular transthyretin, a gene responsible for hereditary transthyretin amyloidosis, by intravitreal injection of an siRNA conjugate into rabbit eyes
Open Access
- 16 December 2023
- journal article
- research article
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 694, 149397
Abstract
No abstract availableKeywords
Funding Information
- Pfizer
- Alnylam Pharmaceuticals
- Ministry of Education, Culture, Sports, Science and Technology (JP20K09774, JP21K09703)
This publication has 19 references indexed in Scilit:
- Toxicological and Pharmacokinetic Properties of QPI-1007, a Chemically Modified Synthetic siRNA Targeting Caspase 2 mRNA, Following Intravitreal InjectionNucleic Acid Therapeutics, 2014
- Long-term survival after liver transplantation in patients with familial amyloid polyneuropathyNeurology, 2012
- RNAi-Based Treatment for Neovascular Age-Related Macular Degeneration by Sirna-027American Journal of Ophthalmology, 2010
- Novel Therapy for Transthyretin–related Ocular AmyloidosisOphthalmology, 2010
- Impact of Liver Transplantation on Transthyretin-Related Ocular Amyloidosis in Japanese PatientsArchives of Ophthalmology (1950), 2010
- Experimental determination and allometric prediction of vitreous volume, and retina and lens weights in Göttingen minipigsVeterinary Ophthalmology, 2008
- Transthyretin-Related Familial Amyloidotic PolyneuropathyArchives of Neurology, 2005
- Clinical improvement and amyloid regression after liver transplantation in hereditary transthyretin amyloidosisThe Lancet, 1993
- Aqueous outflow system in familial amyloidotic polyneuropathy, Portuguese typeGraefe's Archive for Clinical and Experimental Ophthalmology, 1993
- Identification of amyloid prealbumin variant in familial amyloidotic polyneuropathy (Japanese type)Biochemical and Biophysical Research Communications, 1983